Long-term Follow-up Study of Children Previously Primed With GSK Pneumococcal Vaccine (GSK1024850A) and of Unprimed Children

Inclusion Criteria: * Subjects who the investigator believes that their parents/ guardians can and will comply with the requirements of the protocol should be enrolled in the study. * A male or female between, and including, 31 and 34 months of age at the time of the enrolment. * Subjects who previously participated in study NCT00496015 * For the subjects in the primed AP-AP and NAP-pre groups: subjects who received a booster dose of the pneumococcal conjugate vaccine prior to the study amendment 3. * For the subjects in the unprimed group: subjects who received a dose of the meningococcal vaccine GSK134612. * Written informed consent obtained from the parent or guardian of the subject. * Free of obvious health problems as established by medical history and clinical examination before entering into the study. Exclusion Criteria: * Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding enrolment, or planned use during the entire study period. * Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs during the entire study period. * Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of study vaccine and ending 30 days after. * Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be expose…